Mercodia appoints Helena Åsbrink as interim CEO
With more than 20 years of international leadership experience in life science, Åsbrink brings extensive expertise in operational leadership, business development and leading science-driven organisations.
Åsbrink has held several senior leadership positions in the life science industry, including VP Global Operations, Immunodiagnostics at Thermo Fisher Scientific and Site Director at Galderma’s Uppsala site. Most recently, Åsbrink held a role with Nordic responsibility for laboratory medicine and pathology at Unilabs.
As interim CEO, Åsbrink will focus on building on Mercodia’s scientific and technical strengths, deepening customer partnerships and supporting the company’s continued development.
“The opportunity to lead Mercodia brings together my commitment to improving human health and my experience of developing businesses with a strong scientific foundation. I am particularly inspired by the expertise within the team and look forward to working together to build on Mercodia’s established capabilities,” says Helena Åsbrink, interim CEO of Mercodia.
Mercodia develops and manufactures immunoassays and provides specialised bioanalytical services to support research and drug development, with a particular focus on diabetes, obesity and related cardiometabolic conditions.
